Roivant Sciences Ltd. Common Shares ROIV
i
Market dataready · fetched 2026-11-12T14:56:56.036Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T14:56:52.807223022Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T14:56:55.599327+00:00
Roivant Sciences Ltd. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 50.55 | 141.8% | 26.0% | 38.11 | 58.6% | 7.7% |
| 25Δ | 38.52 | 63.8% | 7.2% | |||
| 30Δ | 38.93 | 68.9% | 6.8% | |||
| 35Δ | 42.39 | 55.8% | 5.7% | 39.48 | 67.9% | 5.8% |
| 40Δ | 41.86 | 53.7% | 4.7% | 40.06 | 65.7% | 4.8% |
| 45Δ | 41.43 | 53.1% | 4.1% | 40.56 | 65.1% | 4.2% |
| 50Δ | 41.00 | 52.5% | 3.4% | 41.07 | 65.2% | 3.5% |
| 55Δ | 40.52 | 60.2% | 3.3% | 41.69 | 72.4% | 3.3% |
| 60Δ | 40.03 | 67.9% | 3.1% | |||
| 65Δ | 39.47 | 69.4% | 2.7% | |||
| 70Δ | 38.87 | 71.3% | 2.2% | |||
| 75Δ | 38.05 | 77.9% | 1.9% | |||
| 80Δ | 37.09 | 83.9% | 1.6% | |||
20Δ
- Pseudo strike
- 50.55
- IV
- 141.8%
- B/E move
- 26.0%
- Pseudo strike
- 38.11
- IV
- 58.6%
- B/E move
- 7.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 38.52
- IV
- 63.8%
- B/E move
- 7.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 38.93
- IV
- 68.9%
- B/E move
- 6.8%
35Δ
- Pseudo strike
- 42.39
- IV
- 55.8%
- B/E move
- 5.7%
- Pseudo strike
- 39.48
- IV
- 67.9%
- B/E move
- 5.8%
40Δ
- Pseudo strike
- 41.86
- IV
- 53.7%
- B/E move
- 4.7%
- Pseudo strike
- 40.06
- IV
- 65.7%
- B/E move
- 4.8%
45Δ
- Pseudo strike
- 41.43
- IV
- 53.1%
- B/E move
- 4.1%
- Pseudo strike
- 40.56
- IV
- 65.1%
- B/E move
- 4.2%
50Δ
- Pseudo strike
- 41.00
- IV
- 52.5%
- B/E move
- 3.4%
- Pseudo strike
- 41.07
- IV
- 65.2%
- B/E move
- 3.5%
55Δ
- Pseudo strike
- 40.52
- IV
- 60.2%
- B/E move
- 3.3%
- Pseudo strike
- 41.69
- IV
- 72.4%
- B/E move
- 3.3%
60Δ
- Pseudo strike
- 40.03
- IV
- 67.9%
- B/E move
- 3.1%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 39.47
- IV
- 69.4%
- B/E move
- 2.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 38.87
- IV
- 71.3%
- B/E move
- 2.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 38.05
- IV
- 77.9%
- B/E move
- 1.9%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 37.09
- IV
- 83.9%
- B/E move
- 1.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 55.47% | |
| 53.21% | |
| 52.03% | |
| 51.07% | |
| 51.25% | |
| 51.91% | |
| 51.35% | |
| 54.07% | |
| 50.38% | |
| 50.91% |
Biotechnology
RPRX
Description unavailable
More →RVMD
Description unavailable
More →RXRX
Description unavailable
More →RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic…
More →RZLT
Description unavailable
More →SABS
Description unavailable
More →